Search

Your search keyword '"Khan, Muhammad Shahzeb"' showing total 67 results

Search Constraints

Start Over You searched for: Author "Khan, Muhammad Shahzeb" Remove constraint Author: "Khan, Muhammad Shahzeb" Publisher elsevier Remove constraint Publisher: elsevier
67 results on '"Khan, Muhammad Shahzeb"'

Search Results

1. Contributors

4. Environmental impact of nanomaterials

5. Electrospun fibers: promising materials for oil water separation

6. Contributors

8. Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017

9. Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017

10. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017

11. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017

12. Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017

13. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017

14. Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017

15. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017

16. Eligibility and Projected Benefits of Rapid Initiation of Quadruple Therapy for Newly Diagnosed Heart Failure.

17. Nano-based remediation strategies for micro and nanoplastic pollution.

18. Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status: Insights From the VICTORIA Trial.

19. Patterns, Prognostic Implications, and Rural-Urban Disparities in Optimal GDMT Following HFrEF Diagnosis Among Medicare Beneficiaries.

20. Serial NT-proBNP Measurements and Implementation of Guideline-Directed Medical Therapy.

21. A Phenomapping Tool and Clinical Score to Identify Low Diuretic Efficiency in Acute Decompensated Heart Failure.

22. Polypharmacy and Optimization of Guideline-Directed Medical Therapy in Heart Failure: The GUIDE-IT Trial.

23. Frailty and Its Implications in Heart Failure with Reduced Ejection Fraction: Impact on Prognosis and Treatment.

24. Hospital at Home as a Novel Care Strategy for Worsening Heart Failure.

25. Association of Non-Alcoholic Fatty Liver Disease With in-Hospital Outcomes in Primary Heart Failure Hospitalizations With Reduced or Preserved Ejection Fraction.

26. Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs.

27. Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk.

28. Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA.

29. Management of Heart Failure With Reduced Ejection Fraction.

30. Medication-Attributable Adverse Events in Heart Failure Trials.

31. Trajectory of Decongestion and Mortality in Young Adults with Acute Heart Failure.

32. Effectiveness of Telemedicine Services After Hospitalization for Heart Failure: A Matter of Outcome?

33. Applicability of Vericiguat to Patients Hospitalized for Heart Failure in the United States.

35. Non-Alcoholic Fatty Liver Disease, Heart Failure, and Long-Term Mortality: Insights From the National Health and Nutrition Examination Survey.

36. Reporting and Definition of Kidney Death in Heart Failure Clinical Trials.

37. Utilization of Implantable Cardioverter Defibrillators Among Patients with a Left Ventricular Assist Device: Insights From a National Database.

38. Trends in Heart Failure-Related Mortality Among Older Adults in the United States From 1999-2019.

39. Where Adults with Congenital Heart Disease Die: Insights from the CDC-WONDER Database.

40. Cellulose and its derivatives, coffee grounds, and cross-linked, β-cyclodextrin in the race for the highest sorption capacity of cationic dyes in accordance with the principles of sustainable development.

41. Are We Getting Any Closer to Understanding Congestion?

42. Trends and Characteristics of Hospitalizations in Patients With Heart Transplant.

44. Trends in HF Hospitalizations Among Young Adults in the United States From 2004 to 2018.

46. Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF: From the GUIDE-IT Trial.

47. Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes.

48. Association of Palliative Care Intervention With Health Care Use, Symptom Burden and Advance Care Planning in Adults With Heart Failure and Other Noncancer Chronic Illness.

49. Practical and Evidence-Based Approaches to In-Hospital Decongestion for Heart Failure: Are We There Yet?

Catalog

Books, media, physical & digital resources